Comprehensive Analysis of the Acute Agitation And Aggression Treatment Market 2025-2034: Growth Rates, Trends, and Future Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Projected Compound Annual Growth Rate (CAGR) of the Acute Agitation And Aggression Treatment Market from 2025 to 2034, and What Factors Influence It?
The market for treating acute agitation and aggression has seen significant growth lately. The market size is projected to increase from $5.72 billion in 2024 to $6.05 billion in 2025, with a compound annual growth rate (CAGR) of 5.8%. Factors contributing to the growth during the historical period include advances in pharmacology, escalating clinical research, regulatory approvals, an increase in instances of acute agitation and aggression, and heightened mindfulness about mental health.
The market for treatment of acute agitation and aggression is predicted to witness robust expansion in the ensuing years. The market is projected to reach $7.77 billion by the year 2029, exhibiting a compound annual growth rate (CAGR) of 6.4%. Factors contributing to this anticipated growth during the forecasted period include the increasing elderly population, enhancements in healthcare infrastructure, escalating investment in the pharmaceutical industry, the growth of home-based care, and a rise in disposable income. Key trends to watch during the forecast period are non-pharmacological interventions, precision medicine, artificial intelligence and predictive analytics, community-centered support, and collaboration within the industry.
How Are the key drivers expanding the growth of the Acute Agitation And Aggression Treatment Market?
The forecasted rise in dementia cases is speculated to drive the growth of the acute agitation and aggression treatment market. Dementia is a condition exhibiting symptoms of impaired memory, cognition, and the inability to cope with everyday tasks. Patients often show signs of agitation, which are expressed through actions such as restlessness, repetitive behaviors, and frequent hand gestures. Acute agitation and aggression treatments are crucial for dementia patients as they minimize the risk associated with harmful symptoms, enhance the patient’s lifestyle, and control the root cause of the agitation. As per the Australian Institute of Health and Welfare, a governmental agency based in Australia, in 2022 it was estimated that around 401,300 Australians were suffering from dementia. This number is predicted to double, hitting 849,300 by 2058. Hence, the escalating occurrence of dementia is fuelling the growth of the acute agitation and aggression treatment market.
Get Your Free Sample of the Global Acute Agitation And Aggression Treatment Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp
Who Are the Leading Players Fueling Growth in the Acute Agitation And Aggression Treatment Market?
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc
What Are the Key Trends to Watch in the Acute Agitation And Aggression Treatment Market Over the Coming Years?
In the acute agitation and aggression treatment industry, key players are introducing ground-breaking products and gaining approval, an example being IGALMI (dexmedetomidine). This medicine offers a new alternative for patients suffering from agitation relative to schizophrenia or bipolar disorder. IGALMI (dexmedetomidine), an underneath-the-tongue medication, is designed for the immediate treatment of acute agitation linked with schizophrenia or bipolar I or II disorder in grown-ups. For instance, BioXcel Therapeutics Inc., a biopharmaceutical firm originating from the US, was granted IGALMI (dexmedetomidine) approval by the Food and Drug Administration in April 2022. The drug is fast-acting, taking effect within minutes. It is also short-acting, with its effects lasting for up to 2 hours. This medication can offer a significant enhancement to existing treatment options for critical or terminal conditions.
Get Instant Access to the Global Acute Agitation And Aggression Treatment Market Report with Swift Delivery!
What Are the Major Categories and Their Growth Dynamics in the Acute Agitation And Aggression Treatment Market?
The acute agitation and aggression treatment market covered in this report is segmented –
1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users
Subsegments:
1) By Box Style: Standard Box Action Cameras, Modular Box Action Cameras
2) By Cube Style: Compact Cube Action Cameras, Cube Cameras with Integrated Mounts
3) By Bullet Style: Long, Cylindrical Action Cameras, Mountable Bullet Cameras
4) By Periscope & 360°: 360-Degree Cameras, Periscope Cameras
5) By Other Types: Wearable Action Cameras, Drone Action Cameras, Specialty Action Cameras
Which Regions Are Driving Growth in the Acute Agitation And Aggression Treatment Market?
The countries covered in the acute agitation and aggression treatment market market report include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
What Are the Defining Features of the Acute Agitation And Aggression Treatment Market?
Acute agitation and aggression treatment refers to the medical and therapeutic interventions to manage and reduce the sudden onset of restlessness, irritability, and hostility in patients. These agitated and aggressive behaviors can be symptoms of various underlying conditions, including psychiatric disorders, neurological disorders, or substance use or withdrawal effects.
Browse Through More Similar Reports By The Business Research Company:
Neurodegenerative Disorder Therapeutics Global Market Report 2024
Neuroscience Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report
Neurostimulation Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
